Recently, ImmuneOnco Biopharma, a partner of Shanghai Medicilon Inc., announced that its newly developed immune checkpoint inhibitor has been approved by the National Medical Products Administration (NMPA), which marks the beginning of a new phase of research on the first CD47 fusion protein drug in China.
It is reported that ImmuneOnco Biopharma submitted the IND to NMPA and the clinical I/II trial study permit were approved. Furthermore, ImmuneOnco Biopharma submitted the IND to FDA simultaneously.
Medicilon, located in Shanghai, is a Contract Research Organization (CRO), which offers fully integrated services such as compound synthesis, compound screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicology evaluation, formulation research and new drug registration. The service platforms of Medicilon comply with the international standard and are recognized by the international drug regulatory authorities. The animal facility of Medicilon has been certified by the AAALAC (International Association for the Assessment and Certification of Animals) and the GLP certificate of the China Food and Drug Administration. In addition, the animal facility has also complied with the GLP standard of US FDA. Medicilon helps their clients to achieve their goals faster with an efficient, cost-effective and one-stop professional services.
About ImmuneOnco Biopharma
ImmuneOnco Biopharma was established in June 2015 in Shanghai Zhangjiang High-Tech Park. ImmuneOnco Biopharma is an early stage biopharmaceutical company dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells.